Llwytho...
SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas
Introduction: Prolactinomas are usually benign and respond well to dopamine agonist therapy. However, approximately 20% are resistant, and 10% behave aggressively and persist or recur. Treatment resistance has been associated with ErbB receptor expression, prompting us to conduct a trial of ErbB tar...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Endocr Soc |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Endocrine Society
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553305/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-442 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|